The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Mark Gilbert named chief of Neuro-Oncology Branch at NIH

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

MARK GILBERT was named chief of the Neuro-Oncology Branch at the NIH, within the Center for Cancer Research of NCI.

Gilbert was previously deputy chairman of the Department of Neuro-Oncology at MD Anderson Cancer Center.

The Neuro-Oncology Branch is a cooperative program between the NCI and the National Institute for Neurological Disorders and Stroke. Established in 2000, the NOB became one of the first trans-institutional initiatives at the NIH.

Gilbert has served as co-chair of the Brain Tumor Committee for the Radiation Therapy Oncology Group since 2010, and has been the primary investigator on a number of pivotal studies in the field of neuro-oncology. He is expected to begin his new role in late November.

Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

Rathmell: We must support our junior colleagues
“Empathy and listening is a key place to start”

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
By W. Kimryn Rathmell
Guest Editorial

Weill Cancer Hub East to investigate connections between metabolism and anti-tumor immunity
Weill Cornell, Rockefeller, Princeton and the Ludwig Institute for Cancer Research showcase the power of collaboration

The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 
By Jedd D. Wolchok, Joshua D. Rabinowitz and Sohail Tavazoie
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account